Previous studies showed that pyruvate with Tris buffer improves mechanical and metabolic functions of globally ischemic swine hearts. The purpose of the present study was to evaluate their effects during short periods of moderate regional ischemia. Studies were conducted on 21 swine hearts during maintenance of control flow to the anterior descending (LAD) and circumflex (LCf) coronary arteries and through 15 minutes of LAD ischemia (flow reduced from 47.1-19.0 ml/min). Pyruvate at control coronary flows increased systolic and total shortening at the apex (0.24-0.36 mm, P < 0.01, and 0.34-0.47 mm, P < 0.025, respectively) and increased oxygen extraction (O2 EXT) and consumption (MVO 2 ) across both beds (LAD: O 2 EXT 36.5-48.6%, P< 0.005; MVO2 106.1-130.7 /imol/min, P< 0.05; LCf: O 2 EXT 31.6-43.8%, P < 0.005; MVO 2 125.3-159.3 /imol/min, P< 0.025). Pyruvate during LAD ischemia, as compared with untreated myocardium, increased diastolic and total shortening at the apex (0.21-0.25 mm, P < 0.05, and 0.18-0.31 mm, P < 0.05, respectively) and increased global contractility (left ventricular max dp/dt from 2726-3220 mm Hg/sec, P< 0.05). O 2 EXT and MVO 2 were not further increased in the LAD bed, but glucose utilization, as estimated from the release of 3 H2O from glucose[2-3 H] infusions, was accelerated (3.93-6.05 /imol/min, P < 0.01). O2 EXT and MVO2 in the LCf circuit during LAD ischemia were significantly increased (42.4-52.7%, P < 0.05, and 169.4-189.7 /imol/min, P < 0.05, respectively) . The increases in mechanical function persisted in treated hearts during the immediate postischemic period at 1 and 5 minutes of reflow. Thus, buffered pyruvate effected significant improvements in regional motion both at control and ischemic coronary flows in working swine hearts and was associated with increases both in aerobic and anaerobic metabolism.
MYOCARDIAL ischemia is a potentially reversible biological insult resulting both from insufficient delivery of oxygen and nutrients and inadequate clearance of metabolic products in underperfused tissue. Such a condition quickly sets into motion a complex series of biochemical events which almost immediately impair contractile activity and energy production. Although mechanical function decreases directly with reductions in high energy phosphate stores, the relationship is not a simple one' and may not explain totally the nearly instant cessation of contractile performance noted to result from coronary occlusion. 2 ' 3 Furthermore, although critical impairments in metabolic function occur with advanced stages of ischemia (i.e., curtailments in fatty acid oxidation and glycolysis, 4 alterations in protein and nucleic acid synthesis, 5 and loss of cell membrane transport function), there is preservation of important elements of substrate utilization in early and presumably mild forms of ischemia. Opie 6 reported for dogs that glucose competes more favorably than fatty acids for the residual oxidative metabolism in regionally ischemic hearts and that a major portion of the glucose extracted by ischemic heart muscle is oxidized. Neely and co-workers 7 also noted accelerations in glycolytic flux above control rates in globally ischemic rat hearts during 1 hour of mild reductions in coronary flow.
It is accepted generally that, without stimulation, the ATP derived from glycolysis is insufficient to meet cellular needs. Because both aerobic and anaerobic metabolism of glucose persists in ischemic tissue, it long has been hoped that a mechanism might be found to stimulate further this metabolism and preserve jeopardized myocardium. Initial emphasis centered on the use of a buffered "polarizing" solution containing excess glucose, insulin, and potassium 8 but, for a variety of reasons, 9 the benefits of this treatment remain controversial.
In recent studies, the glycolytic intermediate, pyruvate, 10 buffered with Tris [tris(hydroxymethyl)aminomethane hydrochloride], also has proved beneficial in a globally ischemic working swine heart preparation." These agents collectively enhanced oxidative decarboxylation from pyruvate, modified glucose utilization, maintained high energy phosphate production, improved left ventricular hemodynamic performance, lessened the severity of ischemic injury, and prolonged survival. However, these observations obviously require further corroboration in a variety of other settings and circumstances. The purpose of our studies was to evaluate the effects of these agents in an experimental model of regional myocardial ischemia, focusing specifically on the contractile interactions of normal and ischemic tissues before and during therapeutic interventions. VOL. 43, No. 2, AUGUST 1978 Methods Twenty-one swine of either sex, weighing 34.1-59.9 kg (average 42.4 kg), were studied following anesthesia with pentobarbital (35 mg/kg, iv) and the establishment of controlled positive pressure ventilation with 100% O 2 . Frequent determinations of arterial pH, P02, PCO2, and CO2 combining power were made throughout each study to assure adequacy of ventilation and acid-base balance.
Experimental Preparation
Following bilateral thoracotomy with transternotomy, two separate extracorporeal perfusion circuits were constructed connecting a cannulated femoral artery with the main left and anterior descending coronary arteries (Fig.  1) . The main left coronary artery was perfused via a Gregg cannula inserted retrogradely through the left subclavian artery, and the anterior descending artery was perfused by a cannula positioned in the proximal third of its distribution. Flows in both systems were controlled and regulated by separate low-flow Sarnes perfusion pumps, model 6050. Control perfusion in each circuit was selected by determining that flow which resulted in a perfusion pressure equal to the animal's systolic arterial pressure plus a predetermined line pressure based on the 
FIGURE 1 Illustration of working swine heart model showing various perfusion and sampling cannulae and motion gauges.
A and B refer to the two perfusion circulations for the anterior descending (LAD) and left coronary arteries (LCA); the latter circuit provided the majority of perfusate for the circumflex arterial bed. C and D are the two venous sampling cannulae for the LAD and circumflex circuits. E and F are the motion gauges placed regionally at the apex and base. G (inset) shows further details of these epicardial displacement transducers.
combined resistances of the perfusion tubing and cannula. For the purpose of making certain metabolic measurements, venous cannulae were inserted in the great cardiac vein anteriorly at the level of the anterior descending arterial cannula and laterally at the level of the left marginal vein. This latter catheter was passed by palpation into the coronary sinus but kept anterolateral to the drainage of the middle cardiac vein posteriorly. The hemiazygos vein, which in swine drains directly into the coronary sinus, had been ligated previously. All cannulae were constructed with side ports for sampling arteriovenous differences of oxygen and metabolites across the myocardium. Additional cannulae were placed in the left ventricle and distal aorta to measure pressures. A high fidelity, manometer-tipped pressure device (Statham model P866) was advanced retrogradely from an internal carotid artery to determine left ventricular pressure. A Teflon catheter, 0.10 inch I.D., connected proximally to a P23Db pressure transducer, also was inserted retrogradely into the descending aorta via a femoral artery. Signals from both transducers, together with the electrocardiogram, were displayed on an eight-channel Mark 200 Brush recorder. Signals from the high fidelity, pressure-tipped catheter were differentiated by a direct-coupled, solid state, constant input-impedance differentiator which had a zero phase shift from zero to 90 Hz.
Two specially designed, high frequency displacement transducers, anchored to the heart by 4-mm plunge probes and sutures, were positioned on the epicardial surface in the perfusion distributions of the anterior descending and circumflex arteries, as shown in Figure 1 . Each transducer operated as a variable resistor through a moveable saline bridge in which changes in epicardial displacement were sensed as variations in electrical resistance. The gauges consisted of two separate and movable components, one of which was a stiff, steel-alloy wire attached at a 90° angle to one of the plunge anchor probes. This wire was inserted into a short piece of 0.9% saline-filled polyethylene tubing attached to the second component of the gauge. The polyethylene tubing of this component was in turn joined to a longer piece of Silastic tubing, through the center of which was passed a second thin flexible wire which was attached firmly to the polyethylene tubing. These two wires, one embedded in the myocardium, the other passing through to external instrumentation (excitation source and signal processing), thus made contact through a saline gap. Preliminary bench studies using these transducers demonstrated a flat frequency response in excess of 80 Hz with a response time to 95% steady state displacement of 3 msec.
Data Analyses
Global estimates of left ventricular pump performance were obtained through measurements of heart rate, aortic and left ventricular pressures, and the maximum rate of left ventricular isovolumetric pressure development (max dp/dt) at normal and ischemic coronary flows. Regional left ventricular mechanical performance was similarly determined from the epicardial contractile activity as measured by the two displacement gauges.
Metabolic functions were estimated regionally by determining myocardial oxygen extractions and consumptions, rates of glucose utilization, and the perfusate concentrations of pyruvate and lactate in each of the two perfusion circuits. Oxygen-carrying capacity for hemoglobin was considered uniform in each animal, and extractions were determined from the arteriovenous differences of hemoglobin oxygen saturation/arterial saturation X 100. Oxygen saturations (O2 sat) were measured with an Instrumentation Laboratory Co-Oximeter, model 182. Myocardial oxygen consuption (MVO2) was calculated from coronary flow rates, coronary perfusate hemoglobin concentrations, and hemoglobin oxygen saturations according to the expression: MVO2 (/umol/min) = 1.39 X coronary flow rate (ml/min) x averaged arterial and venous Hb concentrations (g/100 ml) X arterial-venous O2 sat (A%)/22.4 ml/mmol x 0.001 mmol//wnol.
Rates of exogenous glucose utilization were determined by measuring the rate of 3 H 2 O production from glucose[2-3 H]. 12 Tritium in the 2 position of glucose is exchanged with H 2 O in the glycolytic reactions (mainly in the conversion of glucose-6-phosphate to fructose-6-phosphate). The rate of 3 Total serum glucose was measured on a Technicon Auto-Analyzer. Comparative estimations by the glucose oxidase method were in near-perfect agreement with measurements from the Auto-Analyzer and thus excluded the presence of significant levels of other reducing substances. Arterial and venous samples of coronary blood also were collected and centrifuged, and a sample of serum, extracted in perchloric acid, was used to determine total pyruvate and lactate concentrations by the methods of Hohorst 15 and of Bucher et al. 16 Arterial levels of total fatty acid content were measured by the colorimetric procedure of Duncombe."
In separate studies, coronary and systemic arterial blood were collected to measure serum osmolalities before and after infusions of buffer treatment. Serum osmolality was measured on an Advanced Instruments Hi-Precision research osmometer, model 3R, using the depressed freeze-point method.
Finally, the amount of contamination or cross-drainage of venous blood from one perfusion bed to the other was tested with tracer quantities of high molecular weight tritium-labeled dextran dextran[methoxy-3 H], mol. wt. 70,000). After dextran was infused into either the anterior descending or circumflex perfusate, arterial and venous blood was collected at control and ischemic flow rates, centrifuged, and 0.2 ml of serum counted in the Beckman LS-230 liquid scintillation counter. Venous cross-drainage from other beds into the bed perfused with labeled dextran (dilution) was expressed by the ratio: venous counts s/arterial counts s, where S indicated the blood sampled from the same bed as infused with dextran. Venous crossdrainage from the perfusion bed infused with dextran into other beds (contamination or spill-over) was expressed by the ratio: venous counts o/arterial counts s, where O referred to the perfusion bed other than the one infused with dextran. All ratios were multipled by 100 and expressed as percentages.
Experimental Protocol
We compared in the same swine, regional indicators of mechanical and metabolic function in the anterior descending and circumflex circulations before and after treatments with pyruvate and Tris buffer. Sequential data on global hemodynamic performance also were obtained. Flow to the anterior descending circulation was varied from control to ischemic levels, whereas perfusion to the circumflex circuit was held constant at control levels throughout. Ischemia in the anterior descending circuit was achieved by reducing the perfusion pressure to about 60 mm Hg, a level known to effect ischemic changes. 18 The initial study session consisted of sampling data from both beds after 15 minutes of control flow and after 15 minutes of reduced flow in the anterior descending circuit. The heart then was allowed to recover for a minimum of 60 minutes and the study session repeated at identical flows. During one of the two study sessions, selected randomly, 50 mM pyruvate and 50 mM Tris in a 60-to 100-ml water carrier, buffered to a neutral ph prior to administration, were infused at a constant rate into the coronary perfusate over the 30 minutes. The glucose[2-3 H] infusions to measure glucose utilization were begun 10 minutes before each data sampling. Data were labeled according to the flows in the anterior descending bed: control (C), ischemia (I), control immediately preceding the administration of buffered pyruvate (CI), control with treatment (CR % ), and ischemia with treatment (IR,). Specific comparisons of regional mechanical data between C and Cl provided a means of evaluating the extent of recovery from the first ischemic stress. The protocol furnished two sets of observations. By considering the changes within the anterior descending circuit per se, the effects of ischemia and the effects of treatment with pyruvate and Tris could be evaluated separately. By considering the changes within the circumflex system, a measure of the alterations which occur in normally perfused myocardium when adjacent tissue is rendered ischemic also could be determined. In separate protocols, the effects of buffered pyruvate were also studied immediately following the period of ischemia during early reperfusion. Comparisons of these data were made VOL. 43, No. 2, AUGUST 1978 using paired Student's <-tests, and statistical significance was defined for probability values less than 5%.
Last, studies were undertaken to test the reliability and sensitivity of the regional metabolic measurements, using radioactively labeled, high molecular weight dextran. Swine were similarly prepared, instrumented, and perfused. A sequence of control and ischemic flow regulations to the anterior descending circuit again was adopted while keeping circumflex perfusion constant. Ischemia was limited to 15 minutes of flow restriction followed by a 45-to 60-minute recovery period. Four such ischemic exposures were performed for each heart; in either the first two or second two exposures, excess buffered pyruvate was given. In alternate exposures, tritium-labeled dextran was infused into the anterior descending or circumflex coronary arteries beginning 5 minutes before control measurements and 10 minutes before ischemic measurements. Arterial and venous samples from both perfusion beds were counted and compared to estimate the level of dilution and contamination in venous blood between circulations both during conditions of coronary flow restriction and treatment.
Results

Ischemia in Untreated Myocardium
Coronary flow to the anterior descending perfusion system was adjusted from 47.1 ± 2.8 (mean ± SE) to 19.0 ± 1.9 ml/min for 15 minutes in 11 swine (C vs. I data).
Flow in the circumflex system was held constant throughout at 75.6 ± 6.6 ml/min. Coronary perfusion pressure in the anterior descending circuit fell from 151.8 ± 6.6 mm Hg (or 126.8 mm Hg corrected for line resistance) to 59.8 ±8.1 mm Hg (5-10 mm Hg line pressure), P < 0.001. With the exception of left ventricular end-diastolic pressure, which rose significantly {P < 0.05) ( Table 1) , all other parameters of global hemodynamic function were statistically unchanged. However, epicardial shortening in the region of underperfusion (apex motion, Table 2 and Figure 2 ) declined progressively and by 15 minutes had been replaced during systole by a slight aneurysmal bulge (-0.02 mm). In contrast, shortening during protodiastole significantly increased (P < 0.01), but not enough to preserve total shortening (sum of systolic and diastolic motions), which was reduced (P < 0.01). Velocity of systolic shortening also decreased significantly ( P < 0.01). Motion events near the base in the adjacent bed of myocardium perfused from the circumflex circuit were unchanged.
Correlative estimates of metabolic function, based on arterial and venous samplings of coronary perfusate, also were made before and during ischemic exposures. To assist in determining the amount of dilution and contamination (spill-over) between perfusion beds of adjacent drainage, a separate study was conducted in five swine hearts in which radioactively labeled dextran was alternately infused into the anterior descending and circumflex circulations ( Table 3) . At control flows, venous dilution Abbreviations: C, I, Cl, CR,, and IR, are symbols for the several study groups; comparisons between C and Cl data were used to determine the extent of mechanical recovery after the first ischemic stress; HR = heart rate; AoPr = mean aortic pressure; LVEDP = left ventricular end-diastolic pressure; Max dp/dt = maximal rate of left ventricular isovolumetric pressure development; NS = non-significant; P stands for statistical probability values between comparisons in parentheses. 
Record from one swine of progression change in regional motion at the apex following a reduction in coronary flow in the anterior descending coronary circuit. Data displayed from top to bottom include limb lead electrocardiogram (ECG), epicardial phasic excursions from the apex and base, and left ventricular pressures measured from a high fidelity manometer-tipped catheter along with the first differential of this signal. The records are from different times in the study. Panels A are at control coronary flows, panels B are after 10 minutes of coronary flow restriction, and panels C are after 15 minutes of regional ischemia. A progressive decrease in systolic shortening is noted at the apex, accompanied by a progressive increase in protodiastolic shortening. In this example, systolic expansion was observed. Abbreviations: see Methods section for details; Vs = venous sample from same perfusion circuit infused with dextran; As = arterial sample from circuit infused with dextran; Vo = venous sample from opposite perfusion circuit of that infused with dextran.
was small in the anterior descending bed but somewhat greater in the circumflex bed. Ischemia increased the dilutions of venous counts in both circulations, particularly in the circumflex bed. Contamination by the circulation infused with labeled dextran in the other perfusion circuit was minimal at both control and ischemic flows (<10%). Metabolic measurements from the anterior descending circulation are listed in Table 4 . During underperfusion, oxygen extraction was maximized in the ischemic bed, but myocardial oxygen consumption fell 24.1% below control values (P < 0.025). At comparable blood glucose concentrations, exogenous glucose utilization was unchanged from control levels (not significant), and lactate extraction (calculated as the ratio of the difference in arterial and venous concentrations over the arterial concentration X 100) was converted from lactate consumption (+8.4%) at control flows to lactate production (-45.7%) during ischemia. Substrate levels of arterial free fatty acids in these swine average 0.38 ± 0.05 mM.
The greater venous dilutions in the circumflex perfusion circuit (Table 3 ) obscured the directional changes in regional metabolism calculated by the Fick principle. Nonetheless, during ischemia in the anterior descending circulation, oxygen extraction (31.6 ± 2.6 to 42.4 ± 3.7%, P < 0.001), and oxygen consumption (125.3 ± 11.4 to 169.4 ± 12.2 junol/ml, P < 0.001) in the circumflex circuit was significantly increased above control levels. Glucose utilization also increased 126%, P < 0.05. Such enhanced metabolic activity may have resulted from mechanical events (not detected by the displacement gauge at the base) made to compensate for the decrease in motion in the anterior descending perfusion system. 
Effects of Buffered Pyruvate at Control Flows
Intracoronary infusions of pyruvate with Tris (approximately 20-fold increase in perfusate pyruvate levels) resulted in dilation of the coronary vasculature (Cl vs. CR, data). Perfusion pressure in the anterior descending coronary circuit decreased from 144.4 ± 2.6 mm Hg (or 119.4 mm Hg corrected) immediately preceding treatment to 119.4 ± 5.0 mm Hg (or 94.4 mm Hg corrected), P < 0.001. Global hemodynamic measurements were essentially unchanged, although max dp/dt rose 12% (Table 1). Regional epicardial motion at the apex was augmented from pretreatment values with increases noted both in systolic and total shortenings (P < 0.01 and P < 0.025, respectively; Table 2 and Figures 3 and 4 ). Velocity of systolic shortening reached nearly significant increases (0.05 < P < 0.1). Conversely, motion changes at the base were not significantly increased during treatment ( Table  2 ).
In the anterior descending circulation, oxygen extraction and consumption were increased from pretreatment levels (P < 0.005 and P < 0.05, respectively; Table 4 ), whereas rates of glucose utilization were unchanged. Saturation of the cellular capacity to utilize pyruvate following treatment was suggested by the rise in pyruvate concentration in venous blood to slightly greater levels than in arterial blood. Within the limitations of the estimates, this resulted in a calculated small net release of pyruvate (-0.3%). Venous lactate concentrations were also increased above arterial levels (yielding a calculated lactate release of 7.8%) which, in the absence of other evidence of anaerobiasis, most likely reflected one endpoint of the mass action effect of accelerated pyruvate metabolism.
In the circumflex circulation, oxygen extraction (31.6 ± 2.6 to 43.8 ± 4.2%, P < 0.005) and consumption (125.3 ± 11.4 to 159.3 ± 16.3 jumol/min, P < 0.025) were increased with treatment while glucose utilization remained unchanged. Here again, the 18-fold increase in perfusate pyruvate concentrations (2954 ftmol/ml) resulted in slight net cellular releases of pyruvate (-0.9%) and lactate (-12.0%).
Effects of Buffered Pyruvate during Regional Ischemia
With continued infusions of buffered pyruvate, flow in the anterior descending circuit was reduced to levels identical to those in the untreated ischemia trials (19.0 ±1.9 ml/min). Several changes in global and regional mechanical function were observed between I and IR X data (Tables 1 and 2; Figs. 3 and 4 ). Coronary vasodilation was greater with treatment [anterior descending coronary perfusion pressure decreased from 59.8 ±8.1 (I data) to 52.6 ± 4.9 mm Hg (IR X data), P < 0.001], as was the global index of left ventricular contractility (max dp/dt increased 24.5%, P < 0.05). Apical motion in the region of underperfusion improved, with both slight increases noted in systole (0.05 < P < 0.1) and significant increases in protodiastole (P < 0.05), so that together total shortening was augmented 72.2% (P < 0.05). Velocity of systolic shortening also increased slightly (0.05 < P < 0.1). Motion at the base remained uneffected.
There was no further increase in oxygen extraction in the anterior descending coronary circuit as compared with ischemia without treatment. Thus, myocardial oxygen consumption appeared to be primarily determined by the absolute restriction in coronary flow rather than excess availability of substrate. Buffered pyruvate (at somewhat higher perfusate concentrations than during control flows) effected a 53.9% increase in exogenous glucose utilization (P < 0.01) and a 67.4% release of lactate. The latter production of lactate most likely reflected a mixed end-result of accelerated glucose utilization, increased pyruvate concentrations, and anaerobiasis.
In the circumflex circulation (maintained at control perfusions), oxygen extraction and consumption were increased from pretreatment values (42.4 ± 3.7 to 52.7 ± 4.3%, P < 0.05; and 169.4 ± 12.2 to 189.7 ± 13.8 fimol/ml, P < 0.05, respectively) and from values prior to making the anterior descending bed ischemic (43.8 ± 4.2 to 52.7 ± 4.3% and 159.3 ± 16.3 to 189.7 ± 13.8fimol/ml). Glucose utilization was unchanged. There appeared to be a small lactate release with treatment (-13.7%) which may have reflected a spill-over of venous lactate contamination from the anterior descending circulation to the circumflex drainage.
Effects of Buffered Pyruvate during Reperfusion Following Regional Ischemia
We evaluated the duration of effectiveness of pyruvate and Tris in five additional swine, prepared and instrumented as above. Control coronary flows were 61.0 ± 7.0 ml/min and 50.4 ±1.6 ml/min in the anterior descending and circumflex perfusion circuits. Regional ischemia was obtained by reducing flow in the anterior descending bed to 28.6 ± 2.4 ml/min for 15 minutes. Pretreatments with pyruvate and Tris, 50 mM each, were administered as above. Data were compared between treated and untreated study sessions in the same hearts at control and ischemic flows, and at 1, 5, and 10 minutes of reperfusion in the anterior descending circuit ( Table 5 ). A larger variation in the mean data was noted in this smaller study group (compared with those of Tables 1 and 2), and the measurements of contractility and shortening appeared increased. This latter finding may relate in part to a reduction in mean aortic pressure (as compared with the group in Table 1 ) which would tend to augment the indices of ejection and excursion. Again, treatments with pyruvate and Tris significantly increased total shortening in the ischemic myocardium. Increases in systolic shortening, rate of sytstolic shortening, and diastolic shortening were also observed but did not meet criteria for statistical significance. Myocardial oxygen consumption decreased 38.0% (untreated) and 45.2% (treated) in the anterior descending bed and increased 27.0% (untreated) and 5.4% (treated) in the circumflex bed. The observed increases in shortening in treated myocardium persisted into the immediate recovery period following reflow into the anterior descending bed. At 1 and 5 minutes of recovery, total shortening remained statistically increased with lesser changes noted for systolic shortening and rate of shortening in pretreated hearts. By 10.minutes, these differences had largely disappeared, although systolic and total shortenings were still increased slightly. Oxygen consumptions in the anterior descending and circumflex beds during recovery were no different, comparing treated and untreated data. Table 1 ; the symbol R represents recovery period; NS + indicates that, although criteria for statistical significance are not fulfilled, P value is between 0.05 < P < 0.1.
Discussion
The goals of the present study were to review the influence of buffered pyruvate on myocardial contractile performance in a setting of mild regional ischemia. The milder ischemic stress was chosen to optimize the opportunities for recovery through treatment with pyruvate and Tris. The level of perfusion restriction was sufficient, however, in untreated myocardium to cause a dramatic curtailment of regional motion in association with declines in myocardial oxygen consumption and a conversion from consumption to cellular release of lactate. A few comments on the protocol and methods will be discussed first.
Recent evidence from studies on conscious dogs have shown that even brief periods (2-5 minutes) of complete coronary occlusion can depress regional mechanical function for up to 3 hours following reperfusion. 19 In the present study, a delay in recovery following ischemia also was observed, as shown by the slight reductions in systolic and total shortenings and rate of shortening at the apex (see C vs. Cl comparisons in Tables 1 and 2 ). These decreases, however, were insignificant and not nearly as pronounced as those reported when coronary arteries are totally occluded. The accelerated rate of recovery no doubt was related to persistence of some coronary flow in the underperfused myocardium. Randomization of treatment interventions and the interposition of a long recovery interval between ischemic exposures were of added benefit.
Fatty acid consumption and rates of oxidation were not measured here but have been determined previously." In swine hearts perfused globally, at mild levels of ischemia (50% reductions in coronary flow for 15 minutes), there were no significant decreases in fatty acid utilization or 14 CO 2 production from labeled palmitate at serum free fatty acid levels comparable to those reported here. Conversely, pyruvate in excess concentrations was shown to diminish the rates of fatty acid oxidation both in control and ischemic myocardium, 10 ' 20 presumably by competing as a primary substrate with fatty acids for residual oxidative metabolism. Thus, it may be inferred in the present studies that fatty acid metabolism at control and ischemic flows either did not change (untreated trials) or declined in the presence of pyruvate and Tris treatments.
Studies with labeled dextran established the dilutional and contamination patterns of venous drainage in the two circuits under conditions of perfusion restriction and treatment. The data indicated that the samplings, particularly from the anterior descending venous system, were not appreciably influenced by dilution and contamination, and therefore reliably reflected metabolic changes from the perfused tissue.
The rationale for using pyruvate and Tris stemmed from work suggesting that not all metabolic processes are immediately disrupted in mild to moderately ischemic heart muscle. Opie and colleagues 6 ' 21 demonstrated both a preservation in aerobic glycolysis and an acceleration in anaerobic glycolysis in ischemic zones of small volume. Neely et al. 7 noted that glycolytic flux was clearly dependent on the degree of coronary flow restrictions. If coronary flow was reduced to 10% of control values, glucose utilization was inhibited, but if decreased to between 20% and 40% of control flows, glycolysis was en- VOL. 43, No. 2, AUGUST 1978 hanced. ATP derived from glycolysis appears essential in stabilizing the electrical activity of ischemic cells 22 ' 23 and may have a role in supporting contractility. 24 Thus we reasoned that if agents could be identified to stimulate and sustain accelerated glycolysis, benefits might accrue to less than severely ischemic myocardium. Regulation of glycolysis during ischemia is dependent on several enzymatic control points [glycogen phosphorylase, phosphofructokinase, glyceraldehyde-3-P-dehydrogenase (GAPdh), and pyruvate kinase] which vary in importance both with the time and severity of ischemia. 25 GAPdh appears of most importance at longer exposure times and is limited by intracellular buildup of NADH, hydrogen ion, and lactate. 7 ' 25 ' 2h Pyruvate together with Tris buffer originally were selected in hopes of favorably modifying the cytosolic oxidation-reduction ratio NAD/NADH+ (through conversion of pyruvate to lactate) and lessening the effects of ischemic acidosis. Of even greater importance, however, were the observations in initial studies 10 that pyruvate served as a primary substrate for residual oxidation in the Krebs cycle. A 5-fold increase in pyruvate decarboxylation was documented, sufficient to suppress fatty acid utilization and maintain energy production throughout a prolonged survival time. Tris alone in separate studies did not effect similar improvements.
In the studies presented here, pyruvate and Tris produced a variety of mechanical effects in myocardium perfused at normal flows. Systolic contraction at the apex was significantly increased, with smaller increases noted in the velocity of systolic shortening, a less sensitive index of local performance, 27 and left ventricular max dp/dt, an index of global contractility. Motion at the base was unchanged. This is most likely explained by recent data which showed that the heart does not contract uniformly but has significant regional differences with appreciably less shortening occurring at the base. 28 It remains to be determined how pyruvate and Tris act to effect these changes in motion during control flows, but present evidence would not support a mechanism based on the Frank-Starling effect or on increased osmolality. The carriers for pyruvate and Tris (60-100 ml) and glucose[2-3 H] (40-50 ml) represented only a 5% expansion of whole blood volume 29 in the swine studied and were not sufficient to significantly increase left ventricular end-diastolic pressure (Cl to CR X , Table 1 ). In separate studies, it was also noted that 50 mM Tris effected a mean rise in systemic arterial osmolality of only 2.0 mOsmol/kg. During ischemic perfusions, pyruvate and Tris also effected significant increases in global contractility and regional shortenings, particularly during protodiastole. Both Wiggers et al. 30 and Gregg 31 speculated in early reports that ischemic myocardium "attempted to shorten" during systole but was prevented because its force of contraction was too weak to withstand intraventricular pressures. The diastolic motion described here may reflect a delayed expression of this contraction during a time of falling left ventricular tension development.
The effects of pyruvate and Tris were also noted to persist into the early reperfusion period. Although the sensitivity of the changes was somewhat reduced because of the smaller sampling numbers, clearly demonstrable increases in total shortening were noted in treated myocardium for at least 5 minutes following release from 15 minutes of ischemia. No late-occurring post ischemic consequences from the treatments were evident.
The mechanism responsible for the increased inotropic influence during ischemia and reperfusion is not known but may depend ultimately on the availability of excess substrate (pyruvate) for residual oxidative metabolism and on acceleration of anaerobic glycolysis (pyruvate and Tris). Glucose utilization in ischemic myocardium was increased by pyruvate (+53.9%), indicating that the tissue accumulation of lactate was not sufficient to critically impair GAPdh. In separate studies, we asked whether pyruvate and Tris acted to increase mechanical performance in ischemic tissue by local hyperosmolar effects. Because of its low molecular weight and known ability to cross cell membranes, pyruvate would not be expected to have mannitol-like properties. Tris also crosses cell membranes, but its rate of incorporation is slower and less well understood. 32 To evaluate its effect, Tris was infused at identical rates and concentration into the coronary perfusate of five additional swine and resulted in an increase of 15.9 ± 3.0 mOsmol/kg in coronary blood. This incremental change is below the therapeutic levels usually quoted in the papers on mannitol. 33 ' ** Furthermore, the known time course of edema formation in ischemic myocardium does not fit well with the results described here. Powell and co-workers 35 noted in ischemic dog hearts with low-flow underperfusion to the distal anterior descending artery (0.5-1.0 ml/min) that at least 90 minutes of continued ischemia were required to effect obvious and hemodynamically significant cellular edema. Such reductions in coronary flow and times of flow restriction far exceeded those studied here and suggested a slow developmental progression of cell swelling which would not have been appreciable after only 15 minutes of mild ischemia. Thus the idea of Tris acting through mannitollike effects is not supported.
